Glucotrack, Inc. filed a Form 8-K on October 28, 2026, disclosing that a 1-for-2 reverse stock split of its common stock became effective at 4:30 p.m. Eastern Time on October 23, 2026, and that shares began trading on a split-adjusted basis on October 26, 2026.

Key Highlights

  • Reverse split ratio: Every two shares of common stock were automatically combined into one share, effective October 23, 2026 at 4:30 p.m. Eastern Time.
  • Shares outstanding reduced: Common shares outstanding were proportionally reduced from 2,368,237 to approximately 1,184,119 shares.
  • Authorized shares unchanged: The total number of authorized shares of common stock remains 250,000,000.
  • No fractional shares issued: Stockholders who would have received fractional shares were rounded up to the next whole share instead.
  • New CUSIP number: The CUSIP number for the common stock following the reverse stock split is 45824Q879; the ticker symbol remains "GCTK."
  • Stockholder approval: The reverse stock split was approved by stockholders at the 2026 annual meeting on August 18, 2026.
  • Pro forma financial data included: The filing includes unaudited pro forma combined balance sheet and statements of operations reflecting both this split and the prior 1-for-15 reverse stock split that became effective August 28, 2026.

Glucotrack's 1-for-2 Reverse Stock Split: Share Count, Adjusted Financials, and Merger Context

According to the filing, Glucotrack, Inc. (NASDAQ:GCTK) filed a Certificate of Amendment to its Certificate of Incorporation with the Delaware Secretary of State on October 23, 2026, to effect a one-for-two (1-for-2) reverse stock split of its common stock, par value $0.001 per share. The amendment became effective at 4:30 p.m. Eastern Time that day, and the company's transfer agent, VStock Transfer, LLC, is acting as exchange agent. Stockholders of record will receive a transaction statement indicating their post-split holdings; stockholders holding shares through a broker or nominee will have their positions automatically adjusted.

The filing reports that the number of shares outstanding declined from 2,368,237 immediately before the effective time to approximately 1,184,119 shares after the split. Outstanding stock options and warrants were proportionally adjusted along with their exercise prices, the company disclosed. The authorized share count was not affected and remains 250,000,000. The filing also notes that this 1-for-2 reverse stock split follows an earlier 1-for-15 reverse stock split that became effective on August 28, 2026, referred to in the filing as the "August Reverse Stock Split."

Under Item 8.01, the filing includes unaudited pro forma combined financial information reflecting both reverse stock splits and the merger between Glucotrack and Lokahi Therapeutics Inc. The pro forma tables show, for example, that on a post-split basis the net loss per common share - basic and diluted for the year ended December 31, 2025, was $936.60, compared to $31.22 on a pre-split basis, with weighted average common shares outstanding - basic decreasing from 621,094 to 20,703. For the six months ended June 30, 2026, the post-split net loss per common share - basic and diluted was $73.20, compared to $2.44 pre-split.

What Was Disclosed

Glucotrack disclosed a 1-for-2 reverse stock split effective October 23, 2026, reducing shares outstanding from 2,368,237 to approximately 1,184,119, along with a new CUSIP number (45824Q879) and unaudited pro forma financial statements reflecting the merger with Lokahi Therapeutics and both recent reverse stock splits.